Literature DB >> 11156239

A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with late-onset disease.

J Schleutker1, M Matikainen, J Smith, P Koivisto, A Baffoe-Bonnie, T Kainu, E Gillanders, R Sankila, E Pukkala, J Carpten, D Stephan, T Tammela, M Brownstein, J Bailey-Wilson, J Trent, O P Kallioniemi.   

Abstract

Several predisposition loci for hereditary prostate cancer (HPC) have been suggested, including HPC1 at 1q24-q25 (OMIM #601518) and HPCX at Xq27-q28 (OMIM #300147). Genetically homogeneous populations, such as that of Finland, and distinct subsets of families may help to minimize the genetic heterogeneity that complicates the genetic dissection of complex traits. Here, the role of the HPC1, and HPCX loci in a series of Finnish prostate cancer families was studied, especially in subgroups of families defined by age, number of affected cases, and the mode of disease transmission. DNA samples were collected from 57 Finnish HPC families with at least two living prostate cancer patients. Linkage analysis was carried out with 39 microsatellite markers for the HPC1 region and 22 markers for the HPCX region. The maximum two-point LOD score for the HPCX was 2.05 (marker DXS1205, at theta = 0.14), whereas HPC1 LOD scores were all negative. In HOMOG3R analyses, significant evidence of heterogeneity was observed. Subgroup analyses performed to explore the nature of this heterogeneity indicated that families with no male-to-male (NMM) transmission and a late age of diagnosis (>65 years) accounted for most of the HPCX-linked cases. The maximum HPCX LOD score in this subgroup was 3.12 (theta = 0.001). Nonparametric sibling pair analyses gave a peak LOD score of 3.04 (P < 0.000093) for the NMM transmission subgroup. No subgroup showed any positivity for HPC1. This study suggests that the HPCX-linked prostate cancer families represent a distinct subgroup characterized by NMM transmission of disease and late age of diagnosis.

Entities:  

Mesh:

Year:  2000        PMID: 11156239

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

1.  Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer.

Authors:  Annika Rökman; Tarja Ikonen; Eija H Seppälä; Nina Nupponen; Ville Autio; Nina Mononen; Joan Bailey-Wilson; Jeffrey Trent; John Carpten; Mika P Matikainen; Pasi A Koivisto; Teuvo L J Tammela; Olli-P Kallioniemi; Johanna Schleutker
Journal:  Am J Hum Genet       Date:  2002-04-08       Impact factor: 11.025

2.  X-linked tumor suppressors: perplexing inheritance, a unique therapeutic opportunity.

Authors:  Yang Liu; Lizhong Wang; Pan Zheng
Journal:  Trends Genet       Date:  2010-04-29       Impact factor: 11.639

3.  Segregation analysis of 1,546 prostate cancer families in Finland shows recessive inheritance.

Authors:  Sanna Pakkanen; Agnes B Baffoe-Bonnie; Mika P Matikainen; Pasi A Koivisto; Teuvo L J Tammela; Snehal Deshmukh; Liang Ou; Joan E Bailey-Wilson; Johanna Schleutker
Journal:  Hum Genet       Date:  2007-01-03       Impact factor: 4.132

4.  A haplotype at chromosome Xq27.2 confers susceptibility to prostate cancer.

Authors:  Brian L Yaspan; Kate M McReynolds; J Bradford Elmore; Joan P Breyer; Kevin M Bradley; Jeffrey R Smith
Journal:  Hum Genet       Date:  2008-03-19       Impact factor: 4.132

5.  Fine-mapping the 2q37 and 17q11.2-q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancer.

Authors:  Virpi H Laitinen; Tommi Rantapero; Daniel Fischer; Elisa M Vuorinen; Teuvo L J Tammela; Tiina Wahlfors; Johanna Schleutker
Journal:  Int J Cancer       Date:  2014-11-08       Impact factor: 7.396

6.  Genetic heterogeneity in Finnish hereditary prostate cancer using ordered subset analysis.

Authors:  Claire L Simpson; Cheryl D Cropp; Tiina Wahlfors; Asha George; Marypat S Jones; Ursula Harper; Damaris Ponciano-Jackson; Teuvo Tammela; Johanna Schleutker; Joan E Bailey-Wilson
Journal:  Eur J Hum Genet       Date:  2012-09-05       Impact factor: 4.246

7.  Exclusion of the 750-kb genetically unstable region at Xq27 as a candidate locus for prostate malignancy in HPCX1-linked families.

Authors:  Natalay Kouprina; Nicholas C O Lee; Adam Pavlicek; Alexander Samoshkin; Jung-Hyun Kim; Hee-Sheung Lee; Sudhir Varma; William C Reinhold; John Otstot; Greg Solomon; Sean Davis; Paul S Meltzer; Johanna Schleutker; Vladimir Larionov
Journal:  Genes Chromosomes Cancer       Date:  2012-06-26       Impact factor: 5.006

8.  Cancer Progress and Priorities: Prostate Cancer.

Authors:  Kevin H Kensler; Timothy R Rebbeck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-02       Impact factor: 4.254

9.  An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility.

Authors:  Joan P Breyer; Daniel C Dorset; Travis A Clark; Kevin M Bradley; Tiina A Wahlfors; Kate M McReynolds; William H Maynard; Sam S Chang; Michael S Cookson; Joseph A Smith; Johanna Schleutker; William D Dupont; Jeffrey R Smith
Journal:  Am J Hum Genet       Date:  2014-02-27       Impact factor: 11.025

10.  C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk.

Authors:  C M Eklund; T L J Tammela; J Schleutker; M Hurme
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.